Skip to main content
SpringerLink
Log in

Direct-to-Consumer Advertising of Prescription Drugs

Does it Add to the Overuse and Inappropriate Use of Prescription Drugs or Alleviate Underuse?

  • Leading Article
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

The pharmaceutical industry spent over $US4 billion advertising prescription drugs directly to consumers in the US in 2004. The use of direct-to-consumer advertising (DTCA) has been a source of great controversy. Supporters of DTCA argue that it provides an important source of health information for consumers, increases the treatment of under diagnosed conditions and improves medication adherence. Critics argue that it misleads consumers, leads to overuse of medications, drives up prescription drug prices and costs, and harms the doctor-patient relationship.

The impact of DTCA on public health should be viewed within the context of broader problems with underuse, overuse and inappropriate use of prescription drugs. A number of economic and marketing studies have examined the impact of DTCA on demand for prescription drugs. These studies suggest that DTCA expands total market sales but does not have any appreciable effect on market share within the class. In other words, DTCA increases the likelihood of an individual receiving drug treatment but does not have a significant impact on which drug is selected. Much less is known about whether this expanded use addresses the problems with underuse of prescription drugs, or exacerbates problems with inappropriate use or overuse of prescription drugs.

The few studies that have been conducted on these issues suggest that DTCA probably leads to some appropriate use as well as some inappropriate use and overuse of medications. Formal cost-benefit analyses need to be conducted to determine the net effects of DTCA on public health and to inform policy makers charged with protecting the public interest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Food and Drug Administration, Department of Health and Human Services. Guidance for industry: broadcast advertising of prescription drugs, August 1999 [online]. Available from URL: http://www.fda.gov/cder/guidance/1804fnl.htm [Accessed 2005 Feb 15]

    Google Scholar 

  2. Hoek J, Gendall P, Calfee J. Direct-to-consumer advertising of prescription medicines in the United States and New Zealand: an analysis of regulatory approaches and consumer responses. Int J Advertising 2004; 23: 197–227

    Google Scholar 

  3. IMS Health. Top line industry data: promotion [online]. Available from URL: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_49695992_75406357,00.html [Accessed 2005 Feb 15]

    Google Scholar 

  4. 50th Annual 100 leading national advertisers. Advertising Age 2005 Jun 27 [online]. Available from URL: http://www.adage.com/paypoints/buyArticle.cms/login?.articleId=49238&auth= [Accessed 2005 Feb 15]

    Google Scholar 

  5. Calfee JE. What do we know about direct-to-consumer advertising of prescription drugs? Health Aff 2003 Feb 26; 116–9 [online]. Available from URL: http://content.healthaffairs.org/cgi/content/full/hlthaff.w3.116v1/DC1 [Accessed 2005 Feb 15]

    Google Scholar 

  6. Kelly P. DTC advertising’s benefits far outweigh its imperfections. Health Aff 2004 Apr 28; 246–8 [online]. Available from URL: http://content.healthaffairs.org/cgi/content/full/hlthaff.w4.246v1/DC1 [Accessed 2005 Feb 15]

    Google Scholar 

  7. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA 1999 Jan 27; 281 (4): 380–1

    Article  PubMed  CAS  Google Scholar 

  8. Homer AF. Direct-to-consumer advertising: strengthening our health care system. N Engl J Med 2002; 346 (7): 526–8

    Article  Google Scholar 

  9. Weissman JS, Blumenthal D, Silk AJ, et al. Consumers’ reports on the health effects of direct-to-consumer drug advertising. Health Aff 2003 Feb; W3-82-95 [online]. Available from URL: http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w3.82v1 [Accessed 2003 Jun 28]

    Google Scholar 

  10. Food and Drug Administration, Office of Medical Policy, Division of Drug Marketing, Advertising and Communications. Attitudes and behaviors associated with direct-to-consumer (DTC) promotion of prescription drugs: main survey results [online]. Available from URL: http://www.fda.gov/cder/ddmac/dtcindex.htm [Accessed 2005 Feb 15]

  11. Consumer reaction to DTCA of prescription medicines. Prevention Magazine 2002/2003; 45–54

  12. Angell M. The truth about drug companies. New York: Random House, 2004

    Google Scholar 

  13. Mintzes B. Direct to consumer advertising is medicalising normal human experience. BMJ 2002; 324: 908–11

    Article  PubMed  Google Scholar 

  14. Relman AS. Direct-to-consumer advertising: what are the consequences? Testimony before the US Senate Special Committee on Aging; 2003 Jul 22 [online]. Available from URL: http://aging.senate.gov/public/index.cfm?Fuseaction=Hearings.Detail&HearingID=26 [Accessed 2003 Sep 2]

    Google Scholar 

  15. Hollon MF. Direct-to-consumer marketing of prescription drugs. CNS Drugs 2004; 18 (2): 69–77

    Article  PubMed  Google Scholar 

  16. Wolfe SM. Direct-to-consumer advertising: education or emotion promotion. N Engl J Med 2002 Feb 14; 346 (7): 524–6

    Article  PubMed  Google Scholar 

  17. Avorn J. Advertising and prescription drugs: promotion, education, and the public’s health. Health Aff 2003 Feb 26; 104–8 [online]. Available from URL: http://content.healthaffairs.org/cgi/content/full/hlthaff.w3.104v1/DC1 [Accessed 2006 Feb 15]

    Google Scholar 

  18. Bell R, Kravitz R, Wilkes M. The educational value of consumer-targeted prescription drug print advertising. J Fam Pract 2000; 49 (12): 1092–8

    PubMed  CAS  Google Scholar 

  19. Woloshin S, Schwartz LM, Tremmel J, et al. Direct-to-consumer advertising for prescription drugs: what are Americans being sold? Lancet 2001; 358 (9288): 1141–6

    Article  PubMed  CAS  Google Scholar 

  20. Woloshin S, Schwartz LM, Welch HC. The value of benefit data in direct-to-consumer drug ads. Health Aff Web Exclusive 2004 Apr 28; W4: 234–45

    Google Scholar 

  21. Kaphingst KA, Rudd RE, DeJong W, et al. Literacy demands of product information intended to supplement television direct-to-consumer prescription drug advertisements. Patient Educ Couns 2004; 55: 293–300

    Article  PubMed  Google Scholar 

  22. Kaphingst KA, DeJong W. The educational potential of direct-to-consumer prescription drug advertising. Health Aff 2004; 23 (4): 143–50

    Article  Google Scholar 

  23. Kaphingst KA, DeJong W, Rudd RE, et al. A content analysis of direct-to-consumer television prescription drug advertisements. J Health Commun 2004; 9: 515–28

    Article  PubMed  Google Scholar 

  24. Huh J. Is the information ‘fair and balanced’ in direct-to-consumer prescription drug websites? J Health Commun 2004; 9: 529–40

    Article  PubMed  Google Scholar 

  25. Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200–9

    Article  PubMed  CAS  Google Scholar 

  26. Montamat SC, Cusack B. Overcoming problems with polypharmacy and drug misuse. Clin Geriatr Med 1992; 8: 143–58

    PubMed  CAS  Google Scholar 

  27. Gurwitz JH. Suboptimal medication use in the elderly: the tip of the iceberg. JAMA 1994; 272: 316–7

    Article  PubMed  CAS  Google Scholar 

  28. Schmader K, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc 1994; 42: 1241–7

    PubMed  CAS  Google Scholar 

  29. Beers MH, Ouslander JG, Rolllingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151: 1825–32

    Article  PubMed  CAS  Google Scholar 

  30. Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. CMAJ 1994; 150: 1801–9

    PubMed  CAS  Google Scholar 

  31. Lipton HL, Bero LA, Bird JA, et al. Under medication among geriatric outpatients: results of a randomized controlled trial. Annu Rev Gerontol Geriatr 1992; 12: 95–108

    Google Scholar 

  32. Donohue JM, Berndt ER, Epstein AM, et al. Effects of pharmaceutical promotion adherence to guideline treatment of depression. Med Care 2004; 42 (12): 1176–85

    Article  PubMed  Google Scholar 

  33. Wosinska M. Direct-to-consumer advertising and drug therapy compliance. J Mark Res 2005; XLII: 323–32

    Article  Google Scholar 

  34. Spence MM, Cheetham TC, Schweitzer SO, et al. Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005; 62 (5): 544–59

    Article  PubMed  Google Scholar 

  35. Kravitz RL, Epstein RM, Fedlman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants. JAMA 2005; 293 (16): 1995–2002

    Article  PubMed  CAS  Google Scholar 

  36. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346 (7): 498–505

    Article  PubMed  Google Scholar 

  37. Ma J, Stafford RS, Cockburn IM, et al. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clin Ther 2003; 25 (5): 1503–17

    Article  PubMed  Google Scholar 

  38. Berndt ER. The United States’ experience with direct-to-consumer advertising of prescription drugs: what have we learned? International Conference on Pharmaceutical Innovation; 2005 May 25–27; Taipei [online]. Available from URL: http://www.icpi2005.org [Accessed 2006 Feb 15]

    Google Scholar 

  39. Neslin SA. ROI Analysis of Pharmaceutical Promotion (RAPP) study. Hanover (NH): Amos Tuck School of Business, Dartmouth [online]. Available from URL: http://www.rxpromoroi.org/rapp [Accessed 2006 Feb 15]

    Google Scholar 

  40. Iizuka T. What explains the use of direct-to-consumer advertising of prescription drugs? J Ind Econ 2004; 52 (3): 349–79

    Article  Google Scholar 

  41. Rosenthal MB, Berndt ER, Donohue JM, et al. Demand effects of recent changes in prescription drug promotion. The Henry J. Kaiser Family Foundation. 2003 Jun [online]. Available from URL: http://www.kff.org/rxdrugs/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=14380 [Accessed 2005 Feb 16]

    Google Scholar 

  42. Narayanan S, Desiraju R, Chintagunta PK. Return on investment implications for pharmaceutical promotional expenditures: the role of marketing-mix interactions. J Marketing 2004 Oct; 68: 90–105

    Article  Google Scholar 

  43. Wosinska M. Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products. HBS Marketing Research Paper No. 02–04 [online]. Available from URL: http://ssrn.com/abstract=347005 [Accessed 2006 Feb 15]

    Google Scholar 

  44. Hansen RA, Schommer JC, Cline RR, et al. The association of consumer costsharing and direct-to-consumer advertising with prescription drug use. Res Social Adminstrative Pharm 2005; 1: 139–57

    Article  Google Scholar 

  45. Donohue JM, Berndt ER. Direct-to-consumer advertising and choice of antidepressant. J Public Policy Marketing 2004; 23 (2): 115–27

    Article  Google Scholar 

  46. Ling DC, Berndt ER, Kyle MK. Deregulating direct-to-consumer marketing of prescription drugs: effects on prescription and over-the-counter product sales. J Law Econ 2002; XLV: 691–723

    Article  Google Scholar 

  47. Calfee JE, Winston C, Stempski R. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. J Law Econ 2002; 45: 673–90

    Article  Google Scholar 

  48. Iizuka T, Jin GZ. The effect of prescription drug advertising on drug visits. J Econ Manag Strat 2005; 14 (3): 701–27

    Article  Google Scholar 

  49. Brekke KR, Kuhn M. Direct-to-consumer advertising in pharmaceutical markets. J Health Econ 2006; 25: 102–30

    Article  PubMed  Google Scholar 

  50. Henney JE. Challenges in regulating direct-to-consumer advertising. JAMA 2000; 284 (17): 2242

    Article  PubMed  CAS  Google Scholar 

  51. Saul S. Senate leader calls for limits on drug ads. NY Times 2005 Jul 2: Section C 13

    Google Scholar 

  52. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the US. N Engl J Med 2003; 348 (26): 2635–45

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used in preparation of this manuscript. The author has no conflicts of interest to report.

Author information

Authors and Affiliations

  1. Graduate School of Public Health, Department of Health Policy & Management, University of Pittsburgh, Crabtree Hall A613, 130 DeSoto Street, Pittsburgh, PA, 15261, USA

    Julie M. Donohue

Authors
  1. Julie M. Donohue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie M. Donohue.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donohue, J.M. Direct-to-Consumer Advertising of Prescription Drugs. Int J Pharm Med 20, 17–24 (2006). https://doi.org/10.2165/00124363-200620010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00124363-200620010-00002

Keywords

Search

Navigation